Clinical Trials

Classical hematologyMyeloid

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05320198 2026-03-09

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Phase 1/2 Recruiting

150 enrolled

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT04877522 2026-03-06

Asciminib Roll-over Study

Phase 4 Recruiting

347 enrolled

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-02-06

ASC4START

568 enrolled

Phase 2 Active not recruiting

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

112 enrolled

LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT04576156 2025-12-04

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

327 enrolled

47 enrolled 21 charts 2 FDA

Myeloproliferative Disorders, Polycythemia, Thrombocytosis, Primary Myelofibrosis

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Phase 2 Completed

Eosinophilia, Myeloproliferative Disorders

NCT04064060 2025-11-12

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Phase 3 Recruiting

665 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT00726232 2025-10-29

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

Phase 2 Terminated

73 enrolled 25 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Myeloproliferative Disorders

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT04551066 2025-10-21

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Phase 3 Terminated

252 enrolled 18 charts

MyeloidOther hematologic neoplasmOther neoplasm

Myeloproliferative Disorders, Primary Myelofibrosis

NCT02158858 2025-10-08

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Phase 1/2 Completed

336 enrolled

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3 Terminated

177 enrolled 15 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT05153343 2025-10-01

Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative

Phase 1/2 Completed

31 enrolled

Myeloproliferative Disorders

NCT04182100 2025-09-15

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Phase 2 Completed

29 enrolled 15 charts

Myeloproliferative Disorders, Polycythemia Vera

NCT04629508 2025-09-02

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Phase 2 Completed

4 enrolled 10 charts

Myeloproliferative Disorders, Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT03952039 2025-08-28

FREEDOM2

Phase 3 Completed

202 enrolled 23 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04285086 2025-08-13

SURPASS ET

174 enrolled

Phase 2 Active not recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential

NCT05482971 2025-08-13

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

91 enrolled

Myeloproliferative Disorders, Neoplasms, Thrombocythemia, Essential, Thrombocytosis

NCT06468033 2025-08-13

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Phase 3 Recruiting

150 enrolled

Phase 4 Not yet recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT06290765 2025-07-31

PV

70 enrolled

Myeloproliferative Disorders, Polycythemia Vera

NCT05444530 2025-07-20

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Phase 1 Completed

14 enrolled

Myeloproliferative Disorders

NCT04717414 2025-07-10

INDEPENDENCE

Classical hematologyMyeloid

313 enrolled

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

NCT04603001 2025-06-27

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Phase 1 Active not recruiting

260 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04996875 2025-05-30

APEX

Phase 2 Recruiting

140 enrolled

Phase 2 Active not recruiting

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Leukemia, Leukemia, Mast-Cell, Leukemia, Myeloid, Mastocytosis, Myeloproliferative Disorders, Neoplasms, Neoplasms by Site, Neoplasms, Connective Tissue, Skin Diseases, Soft Tissue Neoplasms, Urticaria Pigmentosa, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Mastocytosis, Systemic

NCT01761968 2025-04-30

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

90 enrolled

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05423691 2025-04-13

TREG108

Phase 1 Recruiting

24 enrolled

Phase 1 Active not recruiting

Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Thrombocytosis, Bone Marrow Neoplasms, Primary Myelofibrosis

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

85 enrolled

Phase 1/2 Active not recruiting

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT03386513 2024-12-16

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

179 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Disorders, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03755518 2024-12-12

FREEDOM

Phase 3 Terminated

38 enrolled 23 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04655092 2024-11-08

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Phase 3 Recruiting

67 enrolled

Myeloproliferative Disorders, Polycythemia Vera

NCT06002490 2024-11-08

A Study to Evaluate P1101 in Japanese PV Patients

Phase 3 Completed

21 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Myeloproliferative Disorders, Polycythemia Vera

NCT05260203 2024-11-06

MargheRITA

Phase NA Completed

124 enrolled

Treatment Adherence and Compliance, Amyloidosis, Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Multiple Myeloma, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Neoplasms, Plasma Cell

NCT04637009 2024-08-02

A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

Phase 1 Terminated

20 enrolled

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Pdgfra-Associated Chronic Eosinophilic Leukemia, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Pyloric Stenosis, Hypertrophic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Phase 1 Terminated

249 enrolled 43 charts

Hodgkin Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Phase 2 Terminated

74 enrolled 40 charts

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

NCT01684150 2024-03-26

A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving

Phase 1 Completed

51 enrolled

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05107856 2024-01-31

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Phase 1 Terminated

21 enrolled

Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT05074550 2023-07-24

Safety Evaluation Study for Patients With Polycythemia Vera

Phase 1 Unknown

6 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Polycythemia Vera

NCT04631211 2023-05-25

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Phase 2 Terminated

21 enrolled

Anemia, Aplastic, Myelodysplastic Syndromes, Myeloproliferative Disorders, Thrombocytopenia, Hematologic Neoplasms

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Phase 1/2 Terminated

201 enrolled 71 charts

BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04866056 2022-12-01

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Phase 1/2 Terminated

1 enrolled